2 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
Pharmaceuticals for use in the United States, Canada, European Union, Great Britain, and Israel. About Polyglutamine
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
exclusively licensed AJ201 from AnnJi Pharmaceuticals in the United States, Canada, European Union, Great Britain, and Israel
- Prev
- 1
- Next